Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Dessislava Marinova

Showing results (11-20 of 25) with videos related to

Pageof 3
Sort By:
The Journal of Infectious Diseases|March 23, 2017
Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against TuberculosisSimon Clark, Faye Lanni, Dessislava Marinova, et al.
Tuberculosis (Edinburgh, Scotland)|January 21, 2016
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn miceNacho Aguilo, Santiago Uranga, Dessislava Marinova, et al.
Nature Communications|December 1, 2019
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccinesMario Tovar, Sergio Arregui, Dessislava Marinova, et al.
The Journal of Infectious Diseases|October 24, 2015
Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17-Dependent MechanismNacho Aguilo, Samuel Alvarez-Arguedas, Santiago Uranga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2018
Data-driven model for the assessment of <i>Mycobacterium tuberculosis</i> transmission in evolving demographic structuresSergio Arregui, María José Iglesias, Sofía Samper, et al.
Ebiomedicine|January 22, 2021
Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environmentRaquel Tarancón, Elena Mata, Santiago Uranga, et al.
Nature Communications|July 15, 2017
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosisNacho Aguilo, Jesus Gonzalo-Asensio, Samuel Alvarez-Arguedas, et al.
Plos One|October 3, 2012
Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell deathAdriana Aporta, Ainhoa Arbues, Juan I Aguilo, et al.
The Lancet. Respiratory Medicine|November 25, 2015
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trialFrançois Spertini, Régine Audran, Reza Chakour, et al.
Vaccine|August 23, 2013
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trialsAinhoa Arbues, Juan I Aguilo, Jesus Gonzalo-Asensio, et al.
Pageof 3

Showing results (11-20 of 25) with videos related to

Sort By:
Pageof 3
The Journal of Infectious Diseases|March 23, 2017
Revaccination of Guinea Pigs With the Live Attenuated Mycobacterium tuberculosis Vaccine MTBVAC Improves BCG's Protection Against TuberculosisSimon Clark, Faye Lanni, Dessislava Marinova, et al.
Tuberculosis (Edinburgh, Scotland)|January 21, 2016
MTBVAC vaccine is safe, immunogenic and confers protective efficacy against Mycobacterium tuberculosis in newborn miceNacho Aguilo, Santiago Uranga, Dessislava Marinova, et al.
Nature Communications|December 1, 2019
Bridging the gap between efficacy trials and model-based impact evaluation for new tuberculosis vaccinesMario Tovar, Sergio Arregui, Dessislava Marinova, et al.
The Journal of Infectious Diseases|October 24, 2015
Pulmonary but Not Subcutaneous Delivery of BCG Vaccine Confers Protection to Tuberculosis-Susceptible Mice by an Interleukin 17-Dependent MechanismNacho Aguilo, Samuel Alvarez-Arguedas, Santiago Uranga, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 23, 2018
Data-driven model for the assessment of <i>Mycobacterium tuberculosis</i> transmission in evolving demographic structuresSergio Arregui, María José Iglesias, Sofía Samper, et al.
Ebiomedicine|January 22, 2021
Therapeutic efficacy of pulmonary live tuberculosis vaccines against established asthma by subverting local immune environmentRaquel Tarancón, Elena Mata, Santiago Uranga, et al.
Nature Communications|July 15, 2017
Reactogenicity to major tuberculosis antigens absent in BCG is linked to improved protection against Mycobacterium tuberculosisNacho Aguilo, Jesus Gonzalo-Asensio, Samuel Alvarez-Arguedas, et al.
Plos One|October 3, 2012
Attenuated Mycobacterium tuberculosis SO2 vaccine candidate is unable to induce cell deathAdriana Aporta, Ainhoa Arbues, Juan I Aguilo, et al.
The Lancet. Respiratory Medicine|November 25, 2015
Safety of human immunisation with a live-attenuated Mycobacterium tuberculosis vaccine: a randomised, double-blind, controlled phase I trialFrançois Spertini, Régine Audran, Reza Chakour, et al.
Vaccine|August 23, 2013
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis-based vaccine to enter clinical trialsAinhoa Arbues, Juan I Aguilo, Jesus Gonzalo-Asensio, et al.
Pageof 3